Abstract
Endometrial carcinoma is an estrogen-dependent tumor. It has been generally accepted that progesterone is effective in women with advanced and/or recurrent endometrial carcinoma and that it should be considered in young patients with early stage disease who desire to preserve their fertility. However whether adjuvant endocrine therapy should be performed routinely after surgery especially in patients whose tumor is confined to the uterus is subject to debate. The aim of the present study was to observe the effects of adjuvant endocrine therapy on the prognosis of patients with stage I/II endometrial carcinoma. A retrospective study was carried out from 1992 to 2004 with 168 women admitted to Peking University Peoples Hospital with endometrial carcinomas confined to the uterus. The 60 women who accepted to undergo endocrine therapy for more than 12 months following surgery formed the endocrine therapy group (the mean ± SD therapy duration was 18.2 ± 9.6 months) and the other 108 women served as controls. The study patients received a daily oral dose of 250 mg of medroxyprogesterone acetate (Peking Creative Fortune Pharmaceutical Peking China). The clinical and pathologic characteristics did not differ much between the 2 groups. (excerpt)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Gynecology and Obstetrics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
